Hemostemix (CVE:HEM) Stock Price Up 31% – Here’s What Happened

by · The Cerbat Gem

Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price rose 31% during trading on Thursday . The company traded as high as C$0.23 and last traded at C$0.19. Approximately 480,687 shares traded hands during mid-day trading, a decline of 9% from the average daily volume of 525,664 shares. The stock had previously closed at C$0.15.

Hemostemix Price Performance

The firm has a market capitalization of C$25.50 million, a PE ratio of -5.10 and a beta of 0.20. The stock has a 50-day moving average price of C$0.20 and a 200 day moving average price of C$0.12. The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07.

Hemostemix Company Profile

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

See Also